Clinical Trial Update: Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PI3K/mTOR inhibitors in combination with an oral MEK inhibitor or irinotecan in patients with advanced cancer; study terminated with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• PI3K/mTOR inhibitors (PI3K/mTOR inhibitors)
• oral MEK inhibitor (MEK inhibitor)

Snippet

Sponsor: Pfizer | Conditions: Advanced Cancer | Phase 1 | Status: TERMINATED | Results posted: 2018-10-29